Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesothelin-Targeted CAR-T for Advanced Pancreatic Cancer
NCT05779917Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Mar 2023
- Primary completion
- Mar 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesothelin CAR-T in pancreatic cancer (PC) and solid tumor, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Dose Limiting Toxicity at 6 months. Started Mar 2023; status: recruiting.
02
Drugs
mesothelin CAR-T
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT05779917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779917.